<DOC>
	<DOCNO>NCT00174629</DOCNO>
	<brief_summary>Primary Objective : - To compare response rate genotypic group control group . Secondary Objective : - To determine safety , time treatment failure survival control genotypic arm .</brief_summary>
	<brief_title>GILT Docetaxel - Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must be/have : histologically confirm nonsmall cell lung cancer ( squamous cell carcinoma , large cell adenocarcinoma ; recommend provide full paraffinembedded block least 5 5 section obtain primary tumor , recurrence metastasis , stain , fix formalin/embedded paraffin , mount slide ( 10 micron section ) , well two serum sample two 10ml tube two blood sample ( see appendix X ) ; unresectable metastatic ( stage IV IIIB malignant pleural effusion ) NSCLC ; WHO performance status &lt; 2 ; Adequate bone marrow , hepatic renal function , assess previous 14 day , show follow characteristic : hemoglobin &gt; = 10g/dl blood cell transfusion within previous 2 week ; absolute neutrophil count &gt; 2.0 10^9 cells/l ; platelet count &gt; = 100.10^9 cells/l ; evidence myelodysplastic syndrome abnormal bone marrow reserve ; creatinine &lt; = 1.5 x UNL creatinine clearance &gt; = 60 ml/min ( real calculate ) ; total bilirubin &lt; = UNL ; ASAT ( SGOT ) and/or ALAT ( SGPT ) &lt; = 1.5 x UNL ; alkaline phosphatase &lt; = 5 x UNL ; serum calcium &lt; = 1.1 x UNL ; least one measurable lesion ; previous surgery intervention ( 30 day inclusion study ) allow metastatic disease must demonstrate ; previous radiotherapy allow : less equal 10 % bone marrow irradiated end radiotherapy 21 day prior inclusion study ; patient fully recover toxic effect ; least one measurable target lesion evaluation tumor response irradiate ; patient must accessible treatment followup . The patient enter trial must treat follow participate center ; life expectancy &gt; = 12 week ; The initial diagnostic procedure perform 4 week prior randomization . pregnant lactate woman ( woman childbearing potential must use adequate contraception ) ; prior systemic chemotherapy immunotherapy NSCLC , even neoadjuvant adjuvant therapy ; prior malignancy , except cure nonmelanoma skin cancer , curatively treat situ carcinoma cervix cancer curatively treat nonevidence disease least 5 year ; history clinical symptomatic brain leptomeningeal metastasis ; current peripheral neuropathy neurohearing &gt; = NCICCTG grade 2 except due trauma ; serious illness medical condition , include : congestive heart disease ; prior myocardial infarction within 6 month ; history significant neurologic psychiatric disorder would inhibit understanding give informed consent ; infection require I.V . antibiotic tuberculosis treatment ongoing study entry ; untreated superior vena cava syndrome ; active peptic ulcer ; unstable diabetes mellitus contraindication high dose corticotherapy herpes , herpes zoster , cirrhosis ; hypercalcemia require therapy ; preexist ascitis and/or clinical significant pericardial effusion ; patient whose lesion ( ) assessable radionuclide scan ; history allergy drug contain excipient TWEEN 80Â® ; concurrent treatment investigational drug ; participation clinical trial one investigational agent ( i.e . antibiotic ) device within 30 day study entry . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>